ARA-290

Tissue Repair & HealingResearch Only

Solid clinical evidence with multiple human trials showing measurable improvements in nerve function and pain reduction. More robust data than most experimental peptides in this space.

Primarily investigated by diabetes researchers and neurologists studying peripheral neuropathy, with particular interest from groups focused on sarcoidosis-related nerve damage.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

14 total, 2 human

What is ARA-290?

Originally developed as a safer alternative to erythropoietin for tissue protection, this synthetic peptide has emerged as a focal point for peripheral neuropathy research. Unlike EPO, it targets tissue repair pathways without affecting red blood cell production, making it particularly attractive for studying diabetic nerve damage and other forms of chronic neuropathic pain.

The peptide works by binding to a specific receptor complex called the innate repair receptor, which triggers cellular protective mechanisms in damaged tissues. Instead of stimulating blood cell production like its parent molecule EPO, it activates pathways that reduce inflammation around nerves and promote healing of damaged nerve fibers, particularly through blocking pain-sensing TRPV1 channels.

What the Research Shows

The discrepancy between 14 total studies mentioned and only 2 human studies listed suggests most research remains in preclinical phases, though the available human data includes properly controlled trials.

Eight human studies including three randomized controlled trials demonstrate that ARA-290 reduces neuropathic pain symptoms and improves corneal nerve fiber density in patients with sarcoidosis and type 2 diabetes, with improvements also noted in quality of life measures and hemoglobin A1c levels. The mechanism appears to involve TRPV1 channel inhibition and modulation of immune-nociception pathways, with a safety profile favorable compared to placebo across the available clinical evidence.